Press "Enter" to skip to content

O mercado de doenças ósseas metastáticas está prosperando em todo o mundo com os principais players inteligentes Merck & Co.Inc., Eli Lilly and Company

Zion Market Research has published a new report titled “Metastatic Bone Disease Market – by Treatment (Medication, Radiation Therapy, Surgical Intervention, and Tumor Ablation Therapy), by Origin (Breast, Lung, Thyroid, Kidney, Prostate & Others), and by End User (Hospitals, Specialty Clinics, and Ambulatory Surgical Centers): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017-2024 ”. According to the report, global metastatic bone disease market was valued at approximately USD 12295.6 million in 2017 and is expected to generate revenue from around USD 20,992.7 million by end of 2024, growing at a CAGR of around 7.89% between 2018 and 2024.

Esta pesquisa o ajudará a expandir seus negócios: [Baixe o PDF de amostra grátis deste relatório de pesquisa]

The metastatic bone disease is a condition that arises from cancer spread to the bones at an advanced stage. This condition causes bone degeneration, fractures, severe pain, anemia, and others. This will increase the cost of treatment, duration, and has very few chances of cure and survival. The disease can be diagnosed with the help of CT scan and treatment includes the treatment and control of fractures, pain management, and local tumor control. Treatment options used for the treatment are completely based on the patient’s condition, response, and the status of the disease. The metastatic bone disease is caused due to the widespread of cancer from other parts to the bone this will lead to the weakening and degeneration of bones.

Metastatic bone disease market is mainly driven by the increased prevalence of cancer over a period of time and an increase in awareness among people. As per National Cancer Institute report, every year 439.2 per 100,000 men and women are diagnosed with some type of cancer and it is estimated that in 2018, 1,735,350 new cases of cancer will be diagnosed in the United States. Furthermore, increase in research and development by various pharmaceutical companies and FDA approval for various drugs led to drug launch which is expected to fuel metastatic bone disease market growth. Moreover, various reimbursement policies and strict regulations will allow for better quality product and various initiatives by government and organization to create awareness; this will support the growth of metastatic bone disease market over the forecast period.

Metastatic bone disease market is segmented on the basis of treatment, the origin of metastasis, and end user. On the basis of treatment, the market is segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication therapy will dominate the metastatic bone disease market. On the basis of the origin of metastasis, the market is segmented into breast, lung, thyroid, kidney, and prostate & others. Breast cancer is expected to dominate the market. On the basis of the end user, the market is segmented into hospitals, specialty clinic, and ambulatory surgical centers. Hospital segment is expected to dominate the market over the forecast period.

Baixe o folheto de amostra em PDF GRATUITO para obter mais informações sobre o setor @ CLIQUE AQUI AGORA

North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa are the key regions of metastatic bone disease market. North America is expected to be the largest growing region over the forecast period due to increase in cancer research and development and approval of new drugs. In North America, market growth is mainly driven by the developing regions such as U.S., Canada, and others. Europe is the second largest region over the forecast period and is expected to experience moderate growth. The Asia Pacific is expected to be the fastest growing region over the forecast period and Latin America and the Middle East and Africa are expected to grow moderately over the forecast period.

Some of the key players in metastatic bone disease market include Merck & Co., Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Amgen, Inc., Novartis AG, Bayer AG, BTG Plc, Fresenius Kabi AG , Medtronic, Boston Scientific Corporation, and others.

The report segments the global metastatic bone disease market as follows:

Global Metastatic Bone Disease Market: Treatment Analysis

Medication
Radiation Therapy
Surgical Intervention
Tumor Ablation Therapy

Global Metastatic Bone Disease Market: Origin Analysis

Breast
Lung
Thyroid
Kidney
Prostate
Others

Global Metastatic Bone Disease Market: End User Analysis

Hospitals
Specialty Clinics
Ambulatory Surgical Centers

Procurar Comunicado de Imprensa @ CLIQUE AQUI AGORA

Global Metastatic Bone Disease Market: Regional Analysis

North america
The U.S.
Europe
UK
France
Germany
Asia Pacific
China
Japan
India
Latin America
Brazil
The Middle East and Africa

Hiren Sam Author
Sorry! The Author has not filled his profile.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *